Reaffirming Adverse Events Related to Lung Cancer Survivors' Target Therapies and Their Apparent Effects on Fear of Cancer Progression, Anxiety, and Depression.

Cancer Nurs

Author Affiliations: Department of Nursing, National Taiwan University Hospital (Mrs Yu, and Drs Lai and Lee); Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine (Dr Chu); School of Nursing, College of Medicine, National Taiwan University (Drs Lai and Lee); and Department of Nursing, National Taiwan University Cancer Center (Dr Lai), Taipei; Department of Nursing, Mackay Medical College (Dr Hung and Ms Chan), New Taipei City; Department of Nursing, Da-Yeh University (Dr Chen), Changhua; and Department of Dermatology, Far Eastern Memorial Hospital (Dr Hsu), New Taipei City, Taiwan.

Published: December 2022

Background: Most advanced non-small-cell lung cancer (NSCLC) patients received targeted therapies of epidermal growth factor receptor tyrosine kinase inhibitors. However, few studies reported the relationships between adverse events (AEs) and psychological distress.

Objectives: The aims of this study were to (1) examine the differences in the incidence of AEs, fear of progression (FoP), anxiety, and depression among 3 generations of epidermal growth factor receptor tyrosine kinase inhibitors (first, gefitinib and erlotinib; second, afatinib; third, osimertinib) and (2) examine the difference in levels of FoP, anxiety, and depression between the presence and absence of AEs in NSCLC patients.

Methods: This study used a cross-sectional study design. Patients with NSCLC (N = 120) were recruited from a medical center in northern Taiwan. Adverse events, FoP, anxiety, and depression were assessed by questionnaires.

Results: The incidence rates of photosensitivity, mouth and throat sores, and diarrhea were significantly high in the gefitinib, erlotinib, and afatinib groups, respectively. A lesser proportion of patients experienced AEs in the osimertinib group, compared with those in the gefitinib and erlotinib, and afatinib groups. The incidence rates of FoP, anxiety, and depression were 13.8% to 26.0%, 24.1% to 40.4%, and 17.6% to 40.0%, respectively. Patients with photosensitivity, paronychia, and alopecia had significantly higher levels of FoP, anxiety, and depression.

Conclusion: This study confirmed the priorities of care among 3 generations of epidermal growth factor receptor tyrosine kinase inhibitors in NSCLC patients, using both the Common Terminology Criteria for Adverse Events (CTCAE 4.03) and PRO-CTCAE 1.0. Photosensitivity, paronychia, and alopecia were associated with higher levels of FoP, anxiety, and depression. Therefore, these AEs require further management.

Implications For Practice: Our study suggests a follow-up to address AEs and psychological distress.

Download full-text PDF

Source
http://dx.doi.org/10.1097/NCC.0000000000001147DOI Listing

Publication Analysis

Top Keywords

anxiety depression
24
fop anxiety
24
adverse events
16
epidermal growth
12
growth factor
12
factor receptor
12
receptor tyrosine
12
tyrosine kinase
12
kinase inhibitors
12
gefitinib erlotinib
12

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!